Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway

Gaurav Kaushik, Deep Kwatra, Dharmalingam Subramaniam, Roy A. Jensen, Shrikant Anant, Joshua M.V. Mammen

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Background Malignant melanoma is an aggressive form of skin cancer with limited effective therapeutic options. Melanoma research concentrates on maximizing the effect on cancer cells with minimal toxicity to normal cells. AMP-activated protein kinase (AMPK) is an important regulator of cellular energy homeostasis and has been shown to control tumor progression regulating the cell cycle, protein synthesis, and cell growth and/or survival. Honokiol (HNK) is a biphenolic compound derived from Magnolia officinalis, a plant that has been used in traditional Chinese and Japanese medicine for the treatment of various pathological conditions. Recent studies have shown that HNK has antitumor activity with relatively low toxicity. In this study, we demonstrated that the growth inhibitory effects of HNK on melanoma and melanoma cancer stem cells were mediated through the activation of AMPK and hence AMPK signaling in melanoma cells.

Methods We determined the effects of HNK treatment on various melanoma cell lines. HNK-induced cell growth inhibitory effects were determined using hexosaminidase assay. Protein expression studies were done by immunoblotting. Primary spheroid assay was used to assess stemness by growing single suspension cells in ultralow attachment plates.

Results HNK is highly effective in inhibiting melanoma cells by attenuating protein kinase B/mammalian target of rapamycin and AMPK signaling. HNK showed significant inhibition of the spheroid-forming capacity of melanoma cells and, hence, stemness. HNK significantly decreased the number and size of melanospheres in a dose-dependent manner. Western blot analyses showed enhanced phosphorylation of AMPK in melanoma cells. Furthermore, HNK decreased the cellular adenosine triphosphate pool in a dose-dependent manner with maximum effects observed at 48 hours.

Conclusions The results suggest that HNK can target melanoma cells and mark them for cell death through AMPK signaling. Further studies are warranted for developing HNK as an effective chemopreventive/therapeutic agent in melanoma.

Original languageEnglish (US)
Pages (from-to)995-1002
Number of pages8
JournalAmerican journal of surgery
Volume208
Issue number6
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Keywords

  • AMPK
  • ATP/ADP
  • Melanoma
  • Metabolic pathways
  • Stem cells

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway'. Together they form a unique fingerprint.

Cite this